Objective Systematically evaluate the efficacy and safety of Dupriumabin the treatment of moderate to severe atopic dermatitis(AD). Methods CNKI, VIP database, PubMed, WanFang data, Embase, Web of Science, Cochrane Library and ClinicalTrials.gov were searched to collect RCTs of Dupriumab in the treatment of moderate to severe AD. The retrieval time is from the date of database construction to June 2022. After screening, data extraction and quality evaluation of the obtained literatures, RevMan 5.4 statistical software was used for quantitative analysis. Results 13 studies were included involving 4270 patients. Results of Meta-analysis showed that response rate of IGA [RR=3.64, 95%CI(3.18,4.17), P<0.00001], response rate of EASI-50 [RR=2.49, 95%CI (2.30,2.70), P<0.00001], improvement of EASI [MD =-28.51, 95% CI (-31.86, -25.16), P<0.00001], improvement of NRS [MD =-4.92, 95% CI (-5.49, -4.36), P<0.00001], and improvement of SCORAD [MD= -30.81, 95%CI (-31.01,-30.61) , P<0.00001] in the treatment group were all better than that in the control group, and the difference was statistically significant. In terms of safety, there was no significant difference in adverse event rate between two groups [RR=0.98, 95%CI(0.94,1.02), P=0.38], and the incidence of serious adverse events in the treatment group was lower than that in the control group [RR=0.47, 95%CI (0.33,0.67), P<0.0001], and the difference was statistically significant. Conclusion The current evidences show that Dupriumab is effective in the treatment of moderate to severe AD, which can significantly improve the itching situation, the area of skin lesions and sleeping conditions of patients with good safety.